SARS-CoV-2 infection, vaccination and antibody response pathways in adults: a cohort study in Catalonia | Medicine BMC

  • Ward H, Whitaker M, Flower B, Tang SN, Atchison C, Darzi A et al. Population antibody responses after COVID-19 vaccination in 212,102 individuals. Nat Common. 2022; 13: 907.

    CAS
    Article – Commodity

    Google Scholar

  • Moncunill G, Aguilar R, Ribes M, Ortega N, Rubio R, Salmerón G et al. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve health care workers. EBioMedicine. 2022; 75: 103805.

    CAS
    Article – Commodity

    Google Scholar

  • Wei J, Pouwels KB, Stoesser N, Matthews PC, Diamond I, Studley R et al. Antibody responses and protective relationships in the general population after two doses of ChAdOx1 or BNT162b2 vaccine. NatMed 2022. https://doi.org/10.1038/s41591-022-01721-6.

  • Dashdorj NJ, Wirz OF, Röltgen K, Haraguchi E, Buzzanco AS, Sibai M, et al. Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia. Cell host microbe. 2021; 29: 1738-1743 AH.

    CAS
    Article – Commodity

    Google Scholar

  • Ruggiero A, Piubelli C, Calciano L, Accordini S, Valenti MT, Carbonare LD, et al. Vaccination against SARS-CoV-2 elicits specific atypical responses to IgM in naïve and previously infected individuals with COVID-19. EBioMedicine. 2022; 77: 103888.

    CAS
    Article – Commodity

    Google Scholar

  • Sheikh Muhammed S, Ishu B, Zhao JYC, Zou M, Cohen C, Lustig Y, et al. Systemic and mucosal immunoglobulin A responses are diversely induced in response to SARS-CoV-2 mRNA vaccination and are associated with protection against subsequent infection. Mucosal immunity. 2022. https://doi.org/10.1038/s41385-022-00511-0.

  • Dobaño C, Jiménez A, Rubio R, Alonso S, Ramírez-Morros A, Vidal M et al. COVID-19-based immunization increases antibodies to the nucleocapsid antigen. Precision translation 2022; 240: 26-32.

    Article – Commodity

    Google Scholar

  • Milne G, Hames T, Scotton C, Gent N, Johnsen A, Anderson RM et al. Does infection or vaccination against SARS-CoV-2 result in permanent immunity? Lancet Resper Med. 2021; 9: 1450 – 66.

    CAS
    Article – Commodity

    Google Scholar

  • Peng Q, Zhou R, Wang Y, Zhao M, Liu N, Li S et al. Decline in immune responses against SARS-CoV-2 variants of concern among vaccines in Hong Kong. eBioMedicine. 2022; 77: 103904.

    CAS
    Article – Commodity

    Google Scholar

  • Pajima KL, Dahl RM, Brill MM, Mets E, Rodriguez-Baradas MC, Marconi VC, et al. Efficacy of COVID-19 mRNA Vaccines Against Hospitalization Associated with COVID-19 – Five Veterans Affairs Medical Centers, US, February 1–August 6, 2021. MMWR Morb Mortal Wkly Rep. Rev. 2021; 70: 1294-9

    CAS
    Article – Commodity

    Google Scholar

  • Karachaliou M, Moncunill G, Espinosa A, Castaño-Vinyals G, Jiménez A, Vidal M et al. Infection caused seroprevalence of SARS-CoV-2 and heterogeneity of antibody responses in a general population cohort study in Catalonia Spain. Science Rep. 2021; 11: 21571.

    CAS
    Article – Commodity

    Google Scholar

  • Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid decay of SARS-CoV-2 antibodies in people with mild Covid-19 virus. In Engel J Med. 2020; 383: 1085-107.

    Article – Commodity

    Google Scholar

  • Zimmermann P, Curtis N. Factors affecting the immune response to vaccination. Clin Microbiol Rev.2019; 32: e00084–18.

    CAS
    Article – Commodity

    Google Scholar

  • Obón-Santacana M, Vilardell M, Carreras A, Duran X, Velasco J, Galván-Femenía I et al. GCAT | The genomes of life: a prospective cohort study of the genomes of Catalonia. BMJ is open. 2018; 8: e018324.

    Article – Commodity

    Google Scholar

  • Ortega N, Ribes M, Vidal M, Rubio R, Aguilar R, Williams S et al. Seven-month kinetics of SARS-CoV-2 antibodies and the role of pre-existing antibodies to human coronaviruses. Nat Common. 2021; 12:4740.

    CAS
    Article – Commodity

    Google Scholar

  • Dobaño C, Santano R, Jiménez A, Vidal M, Chi J, Rodrigo Melero N et al. Immunogenicity and cross-reactivity of nucleocapsid antibody to SARS-CoV-2: benefit and limitations in seroprevalence and immunogenicity studies. Translated by Res J Lab Clin Med. 2021. https://doi.org/10.1016/j.trsl.2021.02.006.

  • ECDC. Variables of interest and concern in the EU/EEA.

  • Dobaño C, Vidal M, Santano R, Jiménez A, Chi J, Barrios D et al. Highly sensitive and specific antibody assays to quantify M, A and G immunoglobulins against SARS-CoV-2 antigens. J Clin Microbiol. 2021; 59.

  • The Catalan Ministry of Health. The Catalan Ministry of Health, the Catalan Epidemiological Surveillance System.

  • Gerussi V, Peghin M, Palese A, Bressan V, Visintini E, Bontempo G et al. Vaccine hesitation among Italian patients who recovered from COVID-19 infection toward influenza and Sars-Cov-2 vaccination. Vaccines. 2021; 9: 172.

    CAS
    Article – Commodity

    Google Scholar

  • Nguyen LH, Joshi AD, Drew DA, Merino J, MW, Lou CH, et al. Hesitance and uptake of self-reported COVID-19 vaccine among participants from different racial and ethnic groups in the United States and the United Kingdom. Nat Common. 2022; 13: 636.

    CAS
    Article – Commodity

    Google Scholar

  • Marcotte H, Piralla A, Zuo F, Du L, Cassaniti I, Wan H et al. Immunity to SARS-CoV-2 for up to 15 months after infection. iScience. 2022; 25: 103743.

    CAS
    Article – Commodity

    Google Scholar

  • Dobaño C, Ramírez-Morros A, Alonso S, Vidal-Alaball J, Ruiz-Olalla G, Vidal M et al. Stability and primary determinants of seropositivity and re-infection rates in healthcare workers up to 12.5 months after COVID-19. BMC Med. 2021; 19: 155.

    Article – Commodity

    Google Scholar

  • Faro-Viana J, Bergman ML, Gonçalves LA, Duarte N, Coutinho TP, Borges PC, et al. Population homogeneity of the antibody response to the COVID-19 BNT162b2/Comirnaty vaccine is only reached after the second dose across all adult age groups. Nat Common. 2022; 13:40.

    CAS
    Article – Commodity

    Google Scholar

  • Koerber N, Priller A, Yazici S, Bauer T, Cheng CC, Mijočević H et al. Spike- and nucleocapsid-specific immune dynamics during long-term follow-up and convalescent SARS-CoV-2 vaccination. Nat Common. 2022; 13: 153.

    CAS
    Article – Commodity

    Google Scholar

  • Kuodi P, Gorelik Y, Zayyad H, Wertheim O, Wiegler KB, Jabal KA et al. Relationship between vaccination status and reported incidence of acute post-COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021. Prepress. Epidemics science. 2022.

  • Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC et al. Risk factors for prolonged COVID-19: analyzes of 10 longitudinal studies and electronic health records in the United Kingdom. pre-print. Epidemics science. 2021.

  • Antonelli M, Penfold RS, Merino J, Sodre CH, Molteni E, Perry S, et al. Risk factors and disease profile of SARS-CoV-2 infection after vaccination in UK users of the COVID Symptom Study: a prospective, community-based, nested, controlled study. Lancet infects dis. 2022; 22:43-55.

    CAS
    Article – Commodity

    Google Scholar

  • Bates TA, McBride SK, Leier HC, Guzman G, Lyski ZL, Schoen D et al. Vaccination before or after SARS-CoV-2 infection leads to a strong humoral response and antibodies that effectively neutralize the variant. Sci Immunol. 2022; 7: eabn8014.

    CAS
    Article – Commodity

    Google Scholar

  • Tsang JS, Dobaño C, VanDamme P, Moncunill G, Marchant A, Othman RB, et al. Improving vaccine-induced immunity: can a baseline predict outcome? Immunol directions. 2020; 41: 457-65.

    CAS
    Article – Commodity

    Google Scholar

  • Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Science Rep. 2021; 11:22777.

    CAS
    Article – Commodity

    Google Scholar

  • Lafon E, Jäger M, Bauer A, Reindl M, Bellmann-Weiler R, Wilflingseder D, et al. Comparative analyzes of the effects of IgG/IgA neutralization from three COVID-19 vaccines against variants of concern. J Allergy Clin Immunol. 2022; 149: 1242-1252.e12.

    CAS
    Article – Commodity

    Google Scholar

  • Fraussen J. IgM responses after SARS-CoV-2 vaccination: insights into pre-existing and protective immunity. eBioMedicine. 2022; 77: 103922.

    CAS
    Article – Commodity

    Google Scholar

  • Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L et al. The early neutralizing antibody response to SARS-CoV-2 is dominated by IgA. Sci Transl Med. 2021; 13: eabd2223.

    CAS
    Article – Commodity

    Google Scholar

  • Monroe ABS, Janani L, Cornelius V, Aley BK, Babbage J, Baxter D, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third (booster) dose after two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicenter, randomized, controlled, phase 2 trial. The Lancet. 2021; 398: 2258-76.

    CAS
    Article – Commodity

    Google Scholar

  • Wei J, Stoesser N, Matthews PC, Ayoubkhani D, Studley R, Bell I et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the UK general population. Nat microbiol. 2021; 6: 1140-9.

    CAS
    Article – Commodity

    Google Scholar

  • Collier DA, Ferreira IATM, Kotagiri P, Datir RP, Lim EY, Touizer E et al. Heterogeneity of the age-related immune response to the SARS-CoV-2 BNT162b2 vaccine. temper nature. 2021; 596: 417-22.

    CAS
    Article – Commodity

    Google Scholar

  • Notarte KI, Ver AT, Velasco JV, Pastrana A, Catahay JA, Salvagno GL et al. Effects of age, gender, serostatus, and underlying comorbidities on humoral response after SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review. Crit Rev Clin Lab Sci. 2022; 1-18.

  • Ferrara P, Gianfredi V, Tomaselli V, Polosa R. The effect of smoking on the humoral response to COVID-19 vaccines: a systematic review of epidemiological studies. Vaccines. 2022; 10:303.

    CAS
    Article – Commodity

    Google Scholar

  • Mazereel V, Van Assche K, Detraux J, De Hert M. The COVID-19 vaccine for people with severe mental illness: why, what, and how? Lancet Psychiatry. 2021; 8: 444-50.

    Article – Commodity

    Google Scholar

  • Naruse H, Ito H, Izawa H, Sarai M, Ishii J, Sakaguchi E et al. BNT162b2 mRNA COVID-19 vaccine immunogenicity in patients with cardiovascular disease. J Clin Med. 2021; 10:5

    CAS
    Article – Commodity

    Google Scholar

  • Lee Soo, Moon Ji, Lee Sk, Lee H, Moon S, Chung SJ, et al. Anti-SARS-CoV-2 Spike RBD protein antibody levels after receiving a second dose of ChAdOx1 nCov-19 vaccine (AZD1222) in healthcare workers: no association with age, sex, obesity, and adverse reactions. immune front. 2021; 12: 779212.

    CAS
    Article – Commodity

    Google Scholar